Company intelligence / Profile preview

Help Therapeutics

Nanjing, Jiangsu, Chinaen.helptherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company's lead product HiCM-188 (iPSC-derived cardiomyocyte therapy) received IND approval in China for treating end-stage heart failure. A 1-year follow-up study of HiCM-188 was reported in Nature.

Therapeutic areas: Rare DiseasesEndocrinologyCardiovascularNeurology
Modalities: Induced pluripotent stem cells (iPSC)Stem cell therapyMesenchymal stem cell therapy
Industry: Biotech

Drug pipeline

8 assets

HiCM-188

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Help Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Help Therapeutics.

Explore the full profile